Clift A, Rowen D, Knox L, Griffiths A W, McDermott C J
Sheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield, UK.
Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK.
Muscle Nerve. 2025 Sep;72(3):359-382. doi: 10.1002/mus.28437. Epub 2025 May 23.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that has no cure, and treatments predominantly focus on improving quality of life. Patient-centred care is central to bringing about meaningful improvements to quality of life. This review addresses the lack of consolidated evidence on what matters most to people with ALS (pwALS) by synthesizing 44 preference-based studies covering six different treatment and intervention categories. Data-based convergent synthesis identified five overarching factors influencing preferences: ease of use, accessibility, making life easier, autonomy, and safety/reliability. Simplifying and enhancing accessibility of treatment delivery across disease stages aligns with the nature of neurodegenerative disorders such as ALS, where function declines as the disease progresses. The value in perceived and real control reflects the profound impact ALS has on an individual's independence. Safety and reliability are crucial for people with ALS and are recognized as fundamental requirements for quality healthcare. The themes identified in this review can inform the attributes of preference elicitation methods. Systematically varying the levels of these attributes elicits quantitative measures of preferences. These findings can be used to inform and develop healthcare policy and clinical practice in ALS care. Specifically, preferences related to drug treatments can then be integrated into target product profiles (TPPs) to align drug development with the needs and values of pwALS. Integrating patient preferences into clinical practice promotes patient-centred care, increasing both patient satisfaction and treatment effectiveness.
肌萎缩侧索硬化症(ALS)是一种无法治愈的进行性神经退行性疾病,治疗主要侧重于提高生活质量。以患者为中心的护理对于切实改善生活质量至关重要。本综述通过综合涵盖六种不同治疗和干预类别的44项基于偏好的研究,解决了关于肌萎缩侧索硬化症患者(pwALS)最重要事项缺乏综合证据的问题。基于数据的收敛性综合分析确定了影响偏好的五个总体因素:易用性、可及性、使生活更轻松、自主性以及安全性/可靠性。简化并提高疾病各阶段治疗交付的可及性,符合ALS等神经退行性疾病的特点,即随着疾病进展功能会下降。感知和实际控制中的价值反映了ALS对个人独立性的深远影响。安全性和可靠性对ALS患者至关重要,被视为优质医疗保健的基本要求。本综述中确定的主题可为偏好诱导方法的属性提供参考。系统地改变这些属性的水平可得出偏好的定量测量结果。这些发现可用于为ALS护理中的医疗政策和临床实践提供信息并加以发展。具体而言,与药物治疗相关的偏好随后可纳入目标产品概况(TPP),以使药物开发与pwALS的需求和价值观保持一致。将患者偏好纳入临床实践可促进以患者为中心的护理,提高患者满意度和治疗效果。